IBB News and Press, iShares Biotechnology ETF From 06/25/22

The first five months of the year marked the worst start for the S&P 500 since 1970 ― and the sixth worst back to 1928. Stock valuations have come down, but company earnings remain solid. Earnings will slow, but 20% is hard to imagine, even in a recession. For fur...

BioCryst Pharmaceuticals shares have been clobbered due to both the bear market and the uncertainty relating to its lead developing drug (BCX9930). I believe that the FDA would remove the partial clinical hold on BCX9930 by either year-end or next year. The lead drug (Orladeyo) is...

Allogene's leadership position in allogeneic CAR-T can be rewarding for early investors. However, being a pioneer has its pitfalls. The company has a decent amount of cash. For further details see: Allogene Therapeutics: Multibagger Potential, But Terribly Risky

In the latest 1Q2022 earnings report, the lead medicine Oxbryta continues to generate highly aggressive growth. You can expect even stronger growth due to the recent Oxbryta launch for kids in the EU. There are also adult campaigns in other countries outside of the USA. Two promis...

Mirati will probably not get accelerated approval for adagrasib in 2nd line NSCLC. This will delay their program for two years. However, much of their data is stronger than Amgen's lumakras. For further details see: Mirati: Not Looking Good In 2022, But Stronger Prospect...

Biotech stocks have had a terrible year so far. Patent expirations will force biopharma giants to look towards smaller companies. Pfizer and Vertex are probably going to be the biggest deal makers. IBB is the best way to play a resumption of M&A activity in biotech sector....

Biotech stocks have made record gains on Friday amid signs of heightened deal making activity in the beaten down industry. SPDR S&P Biotech ETF (XBI) and iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) have recorded biggest intraday gains since late 2020 as the subsector outperformed the br...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

In spite of half of our FMP's four building blocks trading in distress-mode, the portfolio/investment strategy is working just fine. Although stocks are no longer expensive, the economy is looking so fragile, posing a great deal of risk for further decline. This year's lead invest...

AVDL's FT218 is going to get delayed further over a patent issue. However, there's a goalpost in sight now, and the date is June 2023. The company is cash-strapped. For further details see: Avadel: Further Delay, But Some Light At The End Of The Tunnel